The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) gave a favorable ruling to Biogen who holds a market exclusivity in the United States until 2028 on their ’514 patent covering the treatment for multiple sclerosis with 480mg dose of dimethyl fumarate. Tecfidera represents 39% of the company’s total…

DEG supported Sterne Kessler and their client, vaping giant, JUUL Labs Inc. in Certain Electronic Nicotine Delivery Systems and Components Thereof, investigation number 337-TA-1139, before the U.S. International Trade Commission. The commission partly affirmed Judge David P. Shaw’s initial determination that Eonsmoke LLC infringed patents for Juul’s electronic nicotine delivery systems. In his November determination,…

DEG is proud to have supported the trial teams of Wilson Sonsini Goodrich & Rosati PC and Ford O’Brien in their defense of Mark Nordlicht and David Levy accused of defrauding bondholders of an oil exploration company. In July, following a nine-week trial both were convicted.  but sought acquittal or a new trial on the…

The U.S. District Court of New Jersey upheld the validity of Bausch Health Companies Inc.’s patent protecting Relistor (methylnaltrexone bromide) tablets and determined Actavis’ infringement of the patent for opioid-induced constipation in patients with chronic non-cancer pain. The case is Bausch Health Cos. Inc. et al., v. Actavis Laboratories FL Inc., case number 16-cv-9038, in…

The Patent Trial and Appeal Board said Caterpillar failed to prove that a Wirtgen America Inc. patent covering a lifting column for road construction machine is invalid. PTAB Upholds Wirtgen Patent in Loss For Caterpillar – Law360

DEG assisted Sterne Kessler on their 337-TA-1067 win before the U.S. International Trade Commission for their client Wirtgen providing depositions, videographers, 2D/3D graphics and hot seat support. Sterne Kessler secured a victory at the ITC striking down Caterpillar Inc.’s effort to invalidate one of the patents held by the German company. In 2017, Wirtgen accused…

DEG worked closely with Finnegan Henderson on this matter and in a final inter partes review decision the Patent Trial and Appeal Board granted Incyte Corp. a victory by ruling Concept Pharmaceuticals Inc.’s patent relating to a potential hair loss treatment was unpatentable. Concert owns a patent with claims covering CTP-543 – a chemical compound…

DEG is proud to have worked with Faeger Drinker (formerly Drinker Biddle) as they defended their long-time client and leader in the global oral health industry against allegations of patent infringement brought by Ivoclar Vivadent AG and other affiliates. In Certain Dental Ceramics, Products Thereof, and Methods of Making the Same, Inv. No. 337-TA-1050, the…

On February 3, 2017, Judge Gregory M. Sleet found in favor of AstraZeneca’s patents covering its diabetes drugs Onglyza and Kombiglyze. U.S. District Judge of Delaware ruled that five generic makers failed to show that two asserted claims of AstraZeneca AB’s U.S. Patent Number RE44,196 are invalid as obvious in light of prior art, saying…

With the assistance of DEG, Rothwell Figg’s Client Roche triumphs over John Hopkins in rare 146 action. On January 26, 2017, Chief Judge Leonhard P. Stark granted 454 Life Sciences (now part of Roche Molecular Diagnostics) complete victory in JHU’s appeal of an Interference decision that awarded priority to 454.  On de novo review of…

Teaming up with Covington in its pro bono representation of a criminal defendant, DEG donated hundreds of hours of graphics and trial presentation consulting services on a several-week-long trial.

A federal judge in Delaware recently upheld a nearly $500 million jury verdict award to medical device firm Masimo Corp., which claimed that Philips Electronics North American Corp., and Philips Medizin System Boblingen, both subsidiaries of Royal Philips, infringed on Masimo Corp. patents. The patents are for non-invasive technology that monitors oxygen in patients’ blood….